SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is seeing renewed community activity driven by ongoing supply reduction rumors, with investors debating the potential for long-term accumulation versus concerns over price performance. Traders are actively monitoring technical chart patterns and discussing whether the current levels offer a strategic entry point for a future rally.

Melania memes are digital collectibles intended to function as an expression of support for and engagement with the values embodied by the symbol MELANIA

Melania Trump

The MELANIA token continues to face intense community backlash and extreme volatility, with market participants actively debating the project's legitimacy amid allegations of insider manipulation and a significant price collapse from its initial peak. Investors remain deeply divided, with some critics labeling it a failed pump-and-dump scheme while others monitor potential developments or future catalysts in hopes of a speculative reversal.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin (CRO) is capturing investor attention following news of a strategic partnership with High Roller Technologies and new staking support on the Upbit exchange. The community is actively debating the coin's long-term potential, with bulls pointing to these institutional developments and native meme coin ecosystems like 'crow with knife' ($CAW) as catalysts, while bears remain skeptical due to past price dilution and performance concerns.

About Mistery On Cro $MERY was born with the idea of being a meme coin on Cronos chain during the exploding 2024 meme coin season. The founder is David Bui, a well-known and seasoned #crofam $CRO investor on Cryptocom products and a big -well respected- personality on X. David minted “Mistery On CRO” on Cronos blockchain with the purpose of making this chain much better, more popular and specially more fun, but aside from serving as a mere “meme”, $MERY has the ultimate goal of also being a utility token that the founder and the team behind will push to bring many benefits to loyal hodlers. Launched in 27/3/2024 at Sydney, Australia, local time 21h00, the 690,000 $CRO presale sold out within 2 hours. The founder burned the LP to a dead wallet and the contract ownership was renounced. $MERY during its first week of launch got instant traction from the OG #crofam community who jumped in and secured bags. We are now a thriving community that will help nurturing and growing the project by sharing with more and more Web3 users.

Mistery

Mistery ($MERY) is trending as a key native meme coin on the Cronos blockchain, with community sentiment driven by its strong correlation with $CRO and the perception of it being 'rug-proof' due to significant ownership by the crypto.com/us exchange. Investors are actively discussing the coin's growth potential and accumulation patterns while comparing its outlook to past meme coin market leaders.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin (XCN) is trending as investors closely watch for the upcoming Q1 2026 Goliath mainnet launch and recent signs of infrastructure positioning, including increased activity in large wallets and international expansion efforts. The community remains divided, with some members actively accumulating in anticipation of a potential breakout while others express skepticism, often citing historical volatility and the project's long development timeline.

Nomad Foods Ltd. operates as a holding company, which manufactures and sells frozen foods for human consumption. The firm offers its products under the brands LUTOSA, la Cocinera, Birds Eye, Iglo, and Findus. The company was founded by Noam Gottesman and Sir Martin E. Franklin on April 1, 2014 and is headquartered in Woking, the United Kingdom.

Nomad Foods Limited

Nomad Foods is currently at the center of investor discussion regarding its attractive valuation, characterized by a low forward price-to-earnings ratio and a well-covered dividend yield that remains a primary draw. While some market participants express frustration over persistent share price stagnation and ongoing industry headwinds, others view the company's active share buyback program and management's own stock purchases as a signal of long-term confidence in the brand's value.

The Graph is an indexing protocol and global API for organizing blockchain data and making it easily accessible with GraphQL. Developers can use Graph Explorer to search, find, and publish all the public data they need to build decentralized applications. The Graph Network makes it possible to build serverless dApps that run entirely on public infrastructure.  GRT is the native token of the network that’s used to coordinate work. GRT is an ERC20 token. Node operators, called Indexers, stake and earn GRT for processing queries. Anyone can delegate GRT to Indexers to secure the network and earn rewards. Curators organize data on The Graph by signaling GRT on useful APIs, called subgraphs. Indexers, Delegators, and Curators work together to organize the data for the crypto economy and maintain a useful global API for DeFi and Web3.

The Graph

The Graph (GRT) is seeing heightened community engagement as investors debate its long-term utility in the AI and Web3 infrastructure sectors despite ongoing price volatility. While some participants express frustration over recent dilution and slow price action, others are actively accumulating tokens, citing upcoming network upgrades and potential sector rotation as key catalysts for a future recovery.

Alchemy Pay

Alchemy Pay is capturing investor interest as the community anticipates the upcoming Alchemy Chain mainnet launch, with traders actively debating its potential to shift from a payment gateway to a core blockchain settlement layer. While some participants are focused on short-term price targets and recent regulatory license acquisitions, others remain cautious, highlighting the high token supply and ongoing dilution concerns surrounding the project.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as community members debate whether the project is a long-term utility-based infrastructure play or an underperforming asset, with intense speculation surrounding potential catalysts like the Clarity Act and the role of major institutional partnerships. While some investors are aggressively accumulating, citing the potential for future adoption and collateralization needs, others are expressing significant frustration over stagnant price action and perceived lack of transparency from the management team.

Fabrinet engages in the provision of optical packaging and electronic manufacturing services to original equipment manufacturers. The firm's engineering services include process design, failure analysis, reliability testing, tooling design, and real-time traceability system. Its manufacturing operations offer sensors, subsystems, customized optics, and optical modules and components. The company was founded by David Thomas Mitchell on August 12, 1999 and is headquartered in George Town, Cayman Islands.

Fabrinet

Fabrinet is currently trending as investors focus on its critical role in optical packaging and data center infrastructure, with heightened attention surrounding upcoming webcasted Q&A sessions at the Optical Fiber Communication Conference. The community is actively debating the stock's long-term growth potential and tactical entry points amid ongoing volatility and significant institutional interest in AI-driven hardware suppliers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Roth Capital analyst Boobalan Pachaiyappan recommended buying shares of Capricor Therapeutics on Friday's selloff.</li><li>B. Riley, meanwhile, raised the firm's price target on CAPR to $63 from $50 and kept a ‘Buy’ rating on the shares.</li><li>The Food and Drug Administration has lifted the previously issued Complete Response Letter and resumed the review of the Biologics License Application for Deramiocel with a decision expected by August 22.</li></ul>Shares of Capricor Therapeutics (CAPR) fell 9% on Friday after the company reported a wider-than-expected Q4 loss but Wall Street analysts raised their price targets on the stock over hopes for an approval of the company’s lead candidate.On the company’s fourth-quarter (Q4) <a href="https://stocktwits.com/news-articles/markets/equity/capricor-reports-wider-quaterly-loss-than-expected-but-all-eyes-are-on-deramiocel/cZduNXsRIad">earnings</a> call, CEO Linda Marban <a href="https://stocktwits.com/news-articles/markets/equity/capr-stock-best-week-month-ceo-rules-out-conditional-deramiocel-approval/cZdDdk4RIa1">rejected</a> the possibility that the Deramiocel therapy could receive only a conditional regulatory decision. The U.S. Food and Drug Administration is now expected to rule on Capricor's application for Deramiocel in the treatment of Duchenne Muscular Dystrophy by August 22, 2026, after reversing course on its previous rejection. DMD is a genetic disorder characterized by muscle degeneration.<h2 class="st-heading-2">Wall Street Take Aways</h2>Roth Capital analyst Boobalan Pachaiyappan recommended buying shares of Capricor Therapeutics on today's selloff. The 8% pullback is a "transient, healthy and short-lived market correction" following the rally post FDA acceptance of Capricor's application of Deramiocel for the treatment of Duchenne muscular dystrophy, the analyst told investors in a research note. Roth would be buying today's "dislocation" and expects the share price to move towards its price target of $41. The firm has a ‘Buy’ rating on Capricor.B. Riley, meanwhile, raised the firm's price target on CAPR to $63 from $50 and kept a ‘Buy’ rating on the shares. The analyst said that its confidence has increased in a potential smooth approval path for Deramiocel ahead of the August 22 decision date, with shares expected to build into the decision as investors digest additional dataset, the analyst told investors in a research note.Piper Sandler raised the firm's price target on CAPR to $58 from $45 and kept an ‘Overweight’ rating on the shares. The firm noted Capricor ended 2025 with cash of $318 million to fund operations through 2027. The FDA has lifted the previously issued Complete Response Letter and resumed the review of the Biologics License Application for Deramiocel with a decision expected by August 22. Optimistically, the label could include the broad Duchenne muscular dystrophy population, not just DMD cardiomyopathy, Piper argues.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CAPR stock remained within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> has gained 138% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-will-delay-release-of-cybercab-until-late-2026-owing-to-safety-issues-fund-manager-predicts/cZdDVgaRIO9">Tesla Will Delay The Release Of Cybercab Until Late-2026 Owing To Safety Issues, Fund Manager Predicts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval

On the company’s fourth-quarter (Q4) earnings call on Thursday, CEO Linda Marban rejected the possibility that the Deramiocel therapy could receive only a conditional approval.

Equity

Eastman Kodak’s shares rallied nearly 12% in extended hours of trading on Thursday after it reported strong growth in its fourth-quarter revenue.&nbsp;Kodak reported consolidated revenues of $290 million in the fourth quarter of 2025, compared with $266 million in the year-ago period, an increase of $24 million or 9%. The rise in revenue was driven by strong performance in Advanced Materials &amp; Chemicals (AM&amp;C) and Print segments.&nbsp;“Kodak ended 2025 with a strong fourth quarter, which has created a foundation for growth in 2026,” said Jim Continenza, Kodak’s Executive Chairman and CEO. “We continue to execute the long-term plan we began in 2019, which focuses on de-levering the company while continuing to invest in our infrastructure and new product innovation”.&nbsp;Kodak ended the year with a cash balance of $337 million, an increase of $136 million from December 31, 2024. The increase was primarily due to the net impact of the Kodak Retirement Income Plan (KRIP) termination and reversion of assets to the company of $153 million.The company reported GAAP net loss of $108 million in Q4 2025, compared with net income of $26 million for Q4 2024. The decline in net income was primarily due to the non-recurring impact of the Kodak Retirement Income Plan ("KRIP") termination and excise tax paid on the reversion of assets to the company.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around KODK stock trended in ‘bullish’ territory amid ‘extremely high’ message volume.&nbsp;One user on Stocktwits called the share rise ‘better than expected’.<stembedurl>https://stocktwits.com/PharmGal/message/647406000</stembedurl>A bullish user said they are optimistic for Kodak in 2026.&nbsp;<stembedurl>https://stocktwits.com/NikkyBenz13/message/647405165</stembedurl>Another bullish user opined that continued growth in Kodak’s Advanced Materials &amp; Chemicals is especially encouraging and could open doors to new markets.&nbsp;<stembedurl>https://stocktwits.com/Judykay/message/647399877</stembedurl>Shares in the company are down 9.4% so far in 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

In this photo illustration, the Eastman Kodak Company logo is seen displayed on a smartphone screen.

Eastman Kodak Stock Rallies After-Hours As Q4 Revenue Jumps On Strong Segment Performance

Kodak reported consolidated revenues of $290 million in the fourth quarter of 2025, compared with $266 million in the year-ago period, an increase of $24 million or 9%.

<ul><li>The company reported no revenue for the period, and ended 2025 with cash, cash equivalents, and marketable securities of about $318.1 million.</li><li>Capricor is now awaiting the U.S. Food and Drug Administration’s decision on the application for Deramiocel by August 22.</li><li>The FDA reversed course on its previous rejection for Deramiocel earlier this week.</li></ul>&nbsp;Shares of Capricor Therapeutics (CAPR) slid down about 2% after-hours on Thursday, after the company reported wider-than-expected quarterly loss, partially offset by optimism for the company’s pipeline.For the fourth quarter, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/340/capricor-therapeutics-reports-fourth-quarter-and-full-year">reported</a> a net loss of $0.62 per share, compared to loss of $0.16 per share in the corresponding quarter of 2024, and more than a Wall Street estimate of a loss of $0.54.The company reported no revenue for the period, and ended 2025 with cash, cash equivalents, and marketable securities of about $318.1 million. The company now believes this to be sufficient to cover anticipated expenses and capital requirements though 2027.<h2 class="st-heading-2">Optimism For Deramiocel Application</h2>The company is now awaiting the U.S. Food and Drug Administration’s decision on the application for Deramiocel by August 22. If approved, the company said that its San Diego GMP manufacturing facility will support a potential commercial launch.“Capricor enters 2026 with important regulatory and clinical momentum as we work toward potential approval of Deramiocel for the treatment of Duchenne muscular dystrophy (DMD),” said Linda Marbán, CEO of Capricor.The FDA is now expected to rule on Capricor's application for Deramiocel in the treatment of Duchenne Muscular Dystrophy by August 22, 2026, after reversing course on its previous rejection. DMD is a genetic disorder characterized by muscle degeneration.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CAPR stock stayed within ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> has gained about 156% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/fly-stock-rallies-on-wall-street-spiking-optimism-after-succesful-alpha-launch/cZdujXtRIaP">FLY Stock Rallies On Wall Street’s Spiking Optimism After Successful Alpha Launch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Capricor Reports Wider Quarterly Loss Than Expected But All Eyes Are On Muscle Disease Therapy

For the fourth quarter, the company reported a net loss of $0.62 per share, compared to loss of $0.16 per share in the corresponding quarter of 2024.

<ul class="summary-bullets"><li>The company swung to profit in Q4 and reported earnings per share of $0.05 versus year-ago loss per share of $0.22.</li><li>Adjusted operating expenses for the fourth quarter of 2025 were $6.5 million compared to $11.9 million for the fourth quarter of 2024.</li><li>On Stocktwits, retail sentiment around DMRC&nbsp;stock trended in ‘extremely bullish’ territory amid ‘high’ message volume.&nbsp;</li></ul>DigiMarc (DMRC) shares rallied 7% during extended hours of trading after it reported a&nbsp;higher-than-expected&nbsp;fourth-quarter (Q4) revenue on Wednesday.&nbsp;DMRC’s total revenue for Q4 2025 was $8.9 million compared to $8.7 million for the fourth quarter of 2024. Analysts on average expected $8.2 million in revenue, as per data from&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://fiscal.ai">Fiscal.ai</a>.&nbsp;<h2 class="st-heading-2">Q4 Snapshot</h2>DigiMarc’s subscription revenue for Q4 2025 came at $5.3 million compared to $5.0 million for the fourth quarter of 2024. The increase reflects $1.4 million of patent license fees earned during the quarter and higher subscription revenue from new and existing commercial contracts, partially offset by a $1.4 million decrease relating to the expiration of two previously disclosed commercial contracts in 2025,&nbsp;the company said.The company's adjusted net income for Q4 2025 was $1.0 million or $0.05 per diluted share compared to adjusted net loss of $4.6 million or $0.22 per diluted share for the fourth quarter of 2024.“Digimarc is capitalizing on the convergence of key trends driving increased demand for our solutions, positioning ourselves to benefit from - not be the casualty of - the relentless advance of AI," said Riley McCormack, Digimarc CEO. "In Q4 2025, we achieved both positive non-GAAP net income and positive free cash flow. Looking ahead to 2026, we expect to generate significant ARR growth."<h2 class="st-heading-2">Expenses Come Down</h2>Operating expenses for the quarter were $10.0 million, compared to $14.4 million for Q4 2024.&nbsp;The decrease was led by lower cash compensation costs of $4.4 million, largely due to lower headcount, and lower professional services costs of $0.6 million, partially offset by higher stock compensation costs of $0.7 million.&nbsp;Adjusted operating expenses for the quarter were $6.5 million compared to $11.9 million for Q4 2024.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around DMRC&nbsp;stock trended in ‘extremely bullish’ territory amid ‘high’ message volume.&nbsp;Shares in the company have fallen 9.4% so far in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Stocktwits, retail sentiment around DMRC stock trended in ‘extremely bullish’ territory amid ‘high’ message volume. 

DigiMarc Stock Rallies After Hours On Q4 Revenue Beat

DMRC’s total revenue for the fourth quarter of 2025 was $8.9 million compared to $8.7 million for the fourth quarter of 2024.

<ul class="summary-bullets"><li>The company said it expects Bumble App Revenue of $171 million to $174 million for Q126.</li><li>In Q4, total revenue decreased 14.3% to $224.2 million, compared to $261.6 million from the year-ago quarter.</li></ul>Shares of Bumble rallied nearly 25% during Wednesday’s extended hours of trading as upbeat outlook for first-quarter revenue cushioned worries from weakness in fourth-quarter earnings.&nbsp;&nbsp;The company said it expects total&nbsp;revenue&nbsp;for Q1 2026 to be in the range of $209 million to $213 million, which includes Bumble App Revenue of $171 million to $174 million. Analysts on average&nbsp;estimate revenue of $210 million.&nbsp;BMBL expects adjusted core profit in the range of $76 million to $80 million for the quarter.<h2 class="st-heading-2">Weak Q4</h2>Total Revenue decreased 14.3% to $224.2 million, compared to $261.6 million from the year-ago quarter. Bumble App revenue also fell 14.8% to $181.0 million, compared to $212.4 million.Bumble’s Total Paying Users slumped 20.5% to 3.3 million, compared to 4.2 million.The company said&nbsp;its fourth quarter net loss was $611.1 million, compared to net earnings of $9.3 million from the year-ago quarter.&nbsp;<h2 class="st-heading-2">FY 2025</h2>In FY2025, Bumble’s total revenue decreased 9.9% to $965.7 million, compared to $1.07 billion. Total Paying Users decreased 11.5% to 3.7 million, compared to 4.1 million.&nbsp;“In 2025, we made the deliberate choice to return Bumble to its women-first foundation, raising the bar on trust and authenticity while addressing pain points our members experience with online dating,” said Whitney Wolfe Herd, Founder &amp; CEO of Bumble Inc.“With the heavy lift of our quality reset behind us, we are accelerating product innovation and prioritizing member experience enhancements. We are building from a stronger base and positioning Bumble for its next chapter of product-led growth,” Herd said.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around BMBL trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;Shares in BMBL have fallen 2.4% year-to-date.&nbsp;

The exterior of Bumble Headquarters on July 15, 2024 in Austin, Texas. 

Bumble Stock Is Rallying Today After Hours – What Is Causing The Bull Run?

The company said it expects total revenue for Q1 2026 to be in the range of $209 million to $213 million. Analysts on average estimate revenue of $210 million. 

<ul class="summary-bullets"><li>The only drug-related adverse events observed are typically anticipated with gene therapy administration, the company noted.</li><li>It added that a proactive, short-course immune modulation regimen in combination with a differentiated construct and industry-leading product purity levels may contribute to a favorable safety profile for RGX-202.&nbsp;</li><li>Sarepta Therapeutics’s FDA-approved DMD gene therapy Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths.</li></ul>REGENXBIO Inc. (RGNX) on Wednesday announced positive interim data from the company’s early-to-mid stage trial of its gene therapy for Duchenne muscular dystrophy.The investigational gene therapy RGX-202 demonstrated evidence of positively changing disease trajectory for the disease in a few patients enrolled in the trial. It further exhibited a favorable safety profile with no serious adverse events and no evidence of liver injury, the company said.The only drug-related adverse events observed are typically anticipated with gene therapy administration, the company noted, while adding that a proactive, short-course immune modulation regimen in combination with a differentiated construct and industry-leading product purity levels may contribute to a favorable safety profile for RGX-202.Sarepta Therapeutics’s (SRPT) FDA-approved DMD gene therapy, Elevidys, came under scrutiny last year over concerns of acute liver failure and associated patient deaths. Duchenne muscular dystrophy (DMD) is a severe, progressive genetic muscle disease affecting mostly boys.<h2 class="st-heading-2">Application Timeline</h2>REGENXBIO now expects to share topline data from the trial in early second quarter and request a meeting with the FDA in mid-2026, ahead of filing an application seeking approval for the gene therapy.In the meantime, the company will continue to enroll participants for its confirmatory trial, which is expected to have about 30 participants. The company said on Wednesday that it expects to have the majority of the trial enrolled at the time of the application submission.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around RGNX stock fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘extremely low’ levels.<a href="https://stocktwits.com/symbol/RGNX">RGNX stock</a> has gained nearly 54% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/joby-aviation-makes-first-steps-towards-faa-certification-of-aircraft/cZdrOkARIBb">Joby Aviation Makes First Steps Towards FAA Certification Of Aircraft</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Regenxbio Says Its Gene Therapy For Muscle Disorder Showed No Evidence Of Liver Injury In Study 

The investigational gene therapy RGX-202 exhibited a favorable safety profile with no serious adverse events and no evidence of liver injury, the company said. 

<ul class="summary-bullets"><li>The onshore pipelines of SOC have been shut down for a decade since the 2015 Refugio Beach oil spill.</li><li>The efforts come at a time when the U.S.-Israel war with Iran has disrupted global supply of oil and other key energy products.</li><li>Sable in December had said that it received an emergency special permit from PHMSA for Santa Ynez Pipeline System Segments.</li></ul>U.S. President Donald Trump is reportedly set to summon authorities under the Defense Production Act to preempt state laws and ease permitting for Sable Offshore Corp. (SOC)&nbsp; to restart significant production from a cluster of offshore platforms in California.According to a Bloomberg News report, a White House official said that any policy announcement would come directly from the president.&nbsp;The efforts come at a time when the U.S.-Israel war with Iran has disrupted global supply of oil and other key energy products due to the blockade of Strait of Hormuz by Iran.&nbsp;The onshore pipelines have been shut down for a decade since the 2015 Refugio Beach oil spill, when a corroded segment of one pipeline ruptured and released hundreds of thousands of gallons of oil near Santa Barbara.Shares of&nbsp;SOC jumped 18% at the time of writing.&nbsp;&nbsp;<h2 class="st-heading-2">SOC’s Feud</h2>California Attorney General Rob Bonta earlier in the month filed a lawsuit against the Trump Administration, challenging the Pipeline and Hazardous Materials Safety Administration’s (PHMSA) orders that “illegally assert” exclusive jurisdiction over two California onshore oil pipelines of Sable offshore which are known as the Las Flores Pipelines or lines CA-324 and CA-325, and allow them to restart operations.Sable in December had said that it received a receipt of an emergency special permit from PHMSA for Santa Ynez Pipeline System Segments.<h2 class="st-heading-2">IEA Announcement</h2>Earlier in the day, the International Energy Agency announced that all its 32 member countries had unanimously agreed to release 400 million barrels of oil from their emergency reserves to help address disruptions in oil markets caused by the war in the Middle East.Retail sentiment around SOC trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in SOC have jumped 59.4% so far in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

A crane ship helps other vessels searching for oil and natural gas near the oil platform offshore the Red Sea in Ras Behar region, Egypt.

Sable Offshore To Reportedly Get Trump Support Via Emergency Law To Restart Production

A White House official said that any policy announcement would come directly from the president, as per a Bloomberg News report. 

<ul class="summary-bullets"><li>Domo also reported EPS of $0.03, while the Street expected the company to post a loss of $0.03 per share.&nbsp;</li><li>Despite the strong results, Lake Street lowered its price target on Domo to $7 from $13 and kept a ‘Hold’ rating on the shares, as per TheFly.&nbsp;</li><li>Cantor Fitzgerald cut the price target on the company to $8 from $13 and maintained an ‘Overweight’ rating on the shares, citing lower overall software multiples.</li></ul>Domo Inc. (DOMO), a cloud software company that leverages artificial intelligence to provide real-time business data to improve executive decision-making, posted fourth-quarter (Q4) results on Tuesday that beat analysts’ expectations.Despite the strong results, Wall Street analysts slashed price targets on the company. Lake Street lowered its price target on Domo to $7 from $13 and kept a ‘Hold’ rating on the shares, as per TheFly.DA Davidson and Cantor Fitzgerald also lowered their price targets on the Utah-based company.<h2 class="st-heading-2">Street Rationale</h2>Lake Street analyst Eric Martinuzzi said the lowered price target reflected a fair takeout price for the growth-challenged SaaS business after the company said in its earnings release that it expects revenue to be flat in FY27 with modest growth in its earnings per share.DA Davidson analyst Lucky Schreiner lowered the price target on Domo to $6 from $10 and kept a ‘Neutral’ rating on the shares. While the firm noted Domo’s strong Q4 results, it said that it is waiting to see more upside to revenue growth prospects before becoming more constructive.Cantor Fitzgerald cut the price target on the company to $8 from $13 and maintained an ‘Overweight’ rating on the shares, citing lower overall software multiples.Based on data from Koyfin, Wall Street has a 12-month average target of $9.58 on Domo shares, representing an upside potential of about 90% compared to the current price levels of $5.04.<h2 class="st-heading-2">Domo Q4 Snapshot</h2>The SaaS company posted a marginal 1% growth in Q4 revenue, coming in at $79.6 million, higher than consensus estimates of $79.03 million. Domo also reported EPS of $0.03, while the Street expected the company to post a loss of $0.03 per share.However, the company refrained from providing specific forward-looking guidance, citing ongoing evaluation of strategic alternatives. The company’s CFO, Tod Crane, however clarified that Domo expects GAAP revenue to remain relatively flat for fiscal year 2027, and modest improvement in non-GAAP EPS and positive adjusted free cash flow.<h2 class="st-heading-2">Retail Sentiment</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/DOMO">DOMO shares</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volumes climbed to ‘extremely high’ levels.Shares of DOMO climbed after the results, and continued to increase on Wednesday. In the past year, DOMO stock has declined more than 37%.Meanwhile, <a href="https://stocktwits.com/symbol/IWM">iShares Russell 2000 ETF</a> (IWM) has climbed by over 25% in the past year, while the <a href="https://stocktwits.com/symbol/VTI">Vanguard Total Stock Market Index Fund ETF</a> (VTI) has gained more than 21%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a US flag is displayed on a smartphone and stock market prices in the background. (Photo Illustration by Romain Doucelin/SOPA Images/LightRocket via Getty Images)

Domo Posted A Double Beat On Q4 Results — So Why Is The Street Slashing Targets?

The cloud software company posted Q4 results on Tuesday, with revenue coming in at $79.6 million, higher than consensus estimates of $79.03 million.

<ul class="summary-bullets"><li>On Stocktwits, retail sentiment around ALDX stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.</li><li>Aldeyra resubmitted its application seeking approval for the drug in July after previous rejections.&nbsp;</li><li>While the agency was initially expected to rule on the application by December, it later extended it until March 16.</li></ul>Shares of Aldeyra Therapeutics (ALDX) garnered retail attention on Stocktwits on Tuesday as the company approaches the date for potential approval of its dry eye treatment Reproxalap.The U.S. Food and Drug Administration (FDA) is slated to rule on the company’s application seeking approval for Reproxalap by March 16. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ALDX stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.Users are sharply divided between hopes for approval following a draft label and a recent procedural extension, and concerns over prior rejections.A Stocktwits user expressed optimism for an imminent approval, saying that the FDA has never rejected a drug so many times.<stembedurl>https://www.stocktwits.com/Dragan7/message/647163937</stembedurl>Another expressed hopes for more information as early as Thursday.<stembedurl>https://www.stocktwits.com/UpAndDownUpAndDown/message/647145449</stembedurl><a href="https://stocktwits.com/symbol/ALDX">ALDX stock</a> has dropped 24% over the past 12 months.<h2 class="st-heading-2">Approval Updates</h2>Aldeyra resubmitted its application seeking approval for Reproxalap in July after <a href="https://stocktwits.com/news-articles/markets/equity/aldeyra-therapeutics-stock-slumps-after-fda-letter/chf7PxrRbe1">previous rejections</a>. &nbsp;While the agency was initially expected to rule on the application by December, it later extended it until March 16 to review the additional submissions made by the company as proof of efficacy of its therapy. The company then said that the FDA made no requests or flagged any specific issues with its application review in a meeting in December.Aldeyra first submitted an application to the FDA for Reproxalap in November 2022, but the agency asked for more trials. The company subsequently resubmitted its application in October 2024 but it was rejected in April with the FDA saying the company’s trials failed to demonstrate its efficacy.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/qure-stock-edges-up-after-hours-as-analyst-flags-reduced-regulatory-uncertainty-after-prasad-fda-exit/cZdY5SrRI7s">QURE Stock Edges Up After Hours As Analyst Flags Reduced Regulatory Uncertainty Following Prasad’s FDA Exit</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aldeyra Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ALDX Stock Garners Retail Interest: Investors Debate Dry Eye Treatment Approval Amid Long Wait

The U.S. Food and Drug Administration is slated to rule on the company’s application seeking approval for Reproxalap by March 16.  

<ul class="summary-bullets"><li>GRPN’s net income from continuing operations was $8.1 million in the fourth quarter 2025 compared with net loss from continuing operations of $50.1 million in the prior year period.&nbsp;</li><li>The company’s active customers were 16.2 million as of December 31, 2025.</li><li>International gross billings were $122.7 million in the fourth quarter 2025, down 1% year-over-year.&nbsp;</li></ul>Shares of Groupon fell 11% during extended hours of trading on Tuesday after it posted a fourth quarter revenue that fell short of Wall Street expectations.&nbsp;The company said its revenue was $132.7 million in the fourth quarter 2025, up 2% compared with the prior year period. It was below analyst expectations of $136.7 million, as per data from Fiscal.ai.&nbsp;Its net income from continuing operations was $8.1 million in the fourth quarter 2025 compared with net loss from continuing operations of $50.1 million in the prior year period.&nbsp;"Our 2025 results represent a landmark achievement in Groupon’s multi-year transformation, as we returned to growth in both billings and revenue for the first time in a decade," said Dusan Senkypl, CEO of Groupon.The company’s active Customers were 16.2 million as of December 31, 2025.<h2 class="st-heading-2">Segment Performance</h2>GRPN’s North America revenue was $98.7 million in the fourth quarter 2025, up 2% compared with the prior year period. Region’s gross billings were $323.8 million in the fourth quarter 2025, up 6% year-over-year.&nbsp;International revenue was $34.0 million in the fourth quarter 2025, up 1% compared with the prior year period. However, International gross billings were $122.7 million in the fourth quarter 2025, down 1% year-over-year. Excluding Giftcloud and Italy, International Local billings increased 16% in the quarter.&nbsp;International unit sales were 3.5 million in the fourth quarter 2025, up 21% sequentially and down 5% compared with the prior year period.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around GRPN trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in the company have fallen 43.4% year-to-date.&nbsp;

Groupon's International gross billings were $122.7 million in the fourth quarter 2025, down 1% year-over-year. 

Groupon Stock Fell 11% After Hours – Here’s Why

The company said its revenue was $132.7 million in the fourth quarter 2025, below analyst expectations of $136.7 million, as per data from Fiscal.ai. 

iShares Trust - iShares Russell 2000 ETF

Up 5%

Down 5%

Show me the results

Which direction is the next 5% move for the S&amp;P 500?

Stocktwits

Which direction is the next 5% move for the S&P 500?

Stocktwits Polls

iShares Russell 2000 ETF

Traders are closely watching IWM's underperformance, as small-cap indices face deeper declines and questions arise about their resilience amid broader market challenges.

Escalating Middle East tensions and surging oil prices are driving significant market uncertainty, with the Strait of Hormuz situation front and center for traders.

Recent economic releases, including downward revised GDP and key inflation data, are fueling market anxiety and influencing expectations for future policy decisions.

Aggressive IWM options trading is surging, with active plays on calls and puts as traders eye critical technical levels and leverage extreme oversold RSI conditions.

Current Price	$247.41
Prev Close	$252.85
Open	$248.94
Dividend Yield	N/A
50-Day Moving Average	$260.40
Beta	N/A
Avg. Volume	40.06M
PE Ratio	N/A

52-Week High	$271.60
52-Week Low	$171.73
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

IWM
iShares Russell 2000 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWM News

IWMiShares Russell 2000 ETF